Fintel reports that on October 20, 2025, D. Boral Capital maintained coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. Analyst Price Forecast Suggests 632.76% Upside As of September ...
The pharmaceutical industry has immense pressure to deliver advanced and novel therapies to patients worldwide but faces monumental challenges in drug development. On average, the journey from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback